Evidence map›Paper›PMID 36505884›Full record

ArticleFrontiers in oncology2022

HLA-BAT1 alters migration, invasion and pro-inflammatory cytokines in prostate cancer.

Aileen M García-Vargas, Yarelis M Roque-Reyes, Desiree M Arroyo-Villegas, Daniel Santiago-Negron, María M Sánchez-Vázquez, Alejandro Rivera-Torres, Andrea C Reyes-Meléndez, Valerie Cardona-Berdecía, Miosotis García-Maldonado, Olga M Víquez and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Aileen M García-VargasDepartment of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, PR, United States.
Yarelis M Roque-ReyesDivision of Cancer Biology, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR, United States.
Desiree M Arroyo-VillegasDivision of Cancer Biology, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR, United States.
Daniel Santiago-NegronDivision of Cancer Biology, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR, United States.
María M Sánchez-VázquezDivision of Cancer Biology, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR, United States.
Alejandro Rivera-TorresDivision of Cancer Biology, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR, United States.
Andrea C Reyes-MeléndezDivision of Cancer Biology, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR, United States.
Valerie Cardona-BerdecíaDivision of Cancer Biology, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR, United States.
Miosotis García-MaldonadoDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, PR, United States.
Olga M VíquezResearch Biobank, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR, United States.
Magaly Martínez-FerrerDivision of Cancer Biology, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR, United States.
University of Puerto Rico System · PRUniversity of Puerto Rico at Río Piedras · PRUniversity of Puerto Rico, Medical Sciences Campus · PRVanderbilt University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) accounts for more than 1 in 5 diagnoses and is the second cause of cancer-related deaths in men. Although PCa may be successfully treated, patients may undergo cancer recurrence and there is a need for new biomarkers to improve the prediction of prostate cancer recurrence and improve treatment. Our laboratory demonstrated that HLA-B-associated transcript 1 (BAT1) was differentially expressed in patients with high Gleason scores when compared to low Gleason scores. BAT1 is an anti-inflammatory gene but its role in PCa has not been identified. The objective of this study is to understand the role of BAT1 in prostate cancer.

Indexed as

animal modelscytokinesinflammationinvasionmigrationprostate cancer

Identifiers

PMID36505884
PMCPMC9727259
OpenAlexW4309708005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.